Key Companies in the Meningococcal Vaccines Market

Why Is the Meningococcal Vaccines Market Expanding?

The Meningococcal Vaccines Market was valued at USD 3.12 billion in 2021 and is projected to reach approximately USD 5.91 billion by 2030, registering a CAGR of 7.29% during the forecast period 2022–2030 (per MRFR Report ID 8622). Multiple independent market sizing studies corroborate a USD 3.5–4.3 billion market range in 2024–2025, with the market poised to cross the USD 6 billion threshold by 2032–2033 at CAGRs ranging 4.5–10% depending on forecast methodology and inclusion of emerging market pentavalent adoption. Market Research Future identifies two structural demand accelerators: a rising global burden of invasive meningococcal disease (IMD) — with the US CDC reporting 503 confirmed and probable cases in 2024, the highest count since 2013 (predominantly serogroup Y) — and a landmark regulatory shift toward pentavalent vaccines (MenABCWY) that consolidate previously separate MenACWY and MenB vaccination series into a single streamlined two-dose schedule.

The conjugate vaccine segment is the current market leader and is forecast to contribute 42–55% of revenues in 2024–2025. This is driven by GSK's Bexsero (MenB) and Menveo (MenACWY), which together generated more than GBP 1.4 billion (approx USD 1.8 billion) in combined sales in 2024 and saw double-digit growth, reaching GBP 1.6 billion for meningitis vaccines in total for FY2025 (GSK IR release, February 4, 2026). The introduction of pentavalent vaccines — Pfizer’s Penbraya (FDA approved October 2023) and GSK’s Penmenvy (FDA approved February 2025) — is the most profound structural change to the product architecture of the market since the rollout of conjugate vaccines, with the Advisory Committee on Immunization Practices (ACIP) voting in April 2025 to recommend pentavalent vaccines whenever both MenACWY and MenB vaccinations are indicated at the same visit. Serogroup B vaccinations are the fastest growing category, as the inclusion of Bexsero in the national immunization programs (NIPs) of Germany and France has spurred impetus for European uptake among both adolescent and newborn cohorts.

Why Are These Companies Leading the Market?

MRFR delineates four key attributes that define category leaders in the Meningococcal Vaccines Market: (1) breadth of serogroup coverage across MenA, MenB, MenC, MenW, MenX, and MenY through complementary portfolio architecture; (2) access to national immunisation programme tender relationships in high-volume markets (Europe, US, Africa, China) that generate predictable multi-year procurement revenues; (3) investment in next-generation pentavalent formats that reduce injection burden and accelerate adolescent vaccine series completion; and (4) manufacturing scale and cold-chain logistics capabilities that enable both high-income market premium pricing and LMIC affordable supply through Gavi and UNICEF procurement channels.

Top 10 Global Meningococcal Vaccines Companies — MRFR Rankings (2026)

MRFR has identified and profiled the following leading meningococcal vaccines companies globally, evaluated on the basis of validated revenue performance, vaccine portfolio breadth across serogroups and formulations, geographic presence, NIP penetration, innovation strategy, and public health impact. All revenue figures have been independently validated against official company filings (Form 20-F, 10-K, 6-K, annual reports, IR releases).

*Rankings based on MRFR analysis of meningococcal-specific revenue, portfolio breadth, and market positioning. Revenue validated from official company filings (Form 20-F, 10-K, 6-K, IR releases). GSK total revenue corrected to GBP 32.67B (FY2025, confirmed 20-F) from prior draft figure of GBP 38.6B. Market share estimates are MRFR analytical calculations. Ranks 8–10 are private entities or government bodies; revenues are estimates or not publicly disclosed.

Detailed Company Profiles

1. GlaxoSmithKline plc | LSE/NYSE: GSK | Brentford, United Kingdom

GlaxoSmithKline plc is the world’s leading meningococcal vaccine company by confirmed revenue, with the most extensive commercial portfolio from a single manufacturer, covering meningococcal serogroups B and ACWY and from 2025, the first GSK pentavalent vaccine covering all five major serogroups. GSK's meningitis franchise is led by Bexsero® (Meningococcal Group B Vaccine), the first MenB vaccine to be approved in Europe (2013) and the US (2015) and has been rolled out into national immunisation programmes in the UK, Italy, Canada, Australia, Germany and France, with Germany’s 2024 NIP inclusion and France’s mandatory newborn MenB vaccine program producing Bexsero’s highest growth cohort in commercial history. The optimal quadrivalent conjugation for completion of the adolescent and travel immunization repertoire is Menveo (MenACWY oligosaccharide conjugate). GSK is present in 175+ countries and had a total FY2025 turnover of GBP 32.67 billion (verified from GSK FY2025 Annual Report on Form 20-F, filed with the SEC, available at SEC EDGAR). Total vaccine sales GBP 9.2 billion in FY2025 (+2% AER, +2% CER). Learn more about GSK’s vaccine portfolio at gsk.com/vaccines.

2. Pfizer Inc. | NYSE: PFE | New York, New York, USA

Pfizer Inc. holds the distinction of being the first company globally to achieve regulatory approval for a pentavalent meningococcal vaccine covering all five major disease-causing serogroups (A, B, C, W, and Y), establishing a first-mover advantage in the next-generation meningococcal vaccine format that defines the market's 2024–2030 growth trajectory. Pfizer's meningococcal portfolio comprises three products: Penbraya (MenABCWY, the first pentavalent, FDA approved October 2023), Nimenrix (MenACWY conjugate, primarily ex-US), and Trumenba (MenB two-dose series, US-approved 2014). Pfizer operates across 175+ countries with more than 88,000 employees and reported FY2025 total revenues of USD 62.6 billion (confirmed via Pfizer Form 10-K, filed February 26, 2026, and FY2025 press release, February 3, 2026). Visit pfizer.com/products/product-detail/penbraya for Penbraya prescribing information.

3. Sanofi S.A. | Euronext: SAN | Paris, France

Sanofi S.A. is one of the founding commercial architects of the meningococcal vaccines market, having developed and commercialised Menactra — the first MenACWY conjugate vaccine to achieve US FDA approval — and currently anchoring its position through MenQuadfi (meningococcal groups A, C, Y, and W conjugate vaccine), a next-generation quadrivalent conjugate vaccine first approved by the FDA in April 2020 and expanded with an infant indication in May 2025. Sanofi operates across 100+ countries and reported FY2025 total net sales of EUR 43.6 billion (confirmed via Sanofi Q4 2025 press release, January 29, 2026, representing 9.9% growth at constant exchange rates and at the upper end of guidance). Sanofi's Meningitis, Travel and Endemic Vaccines sales in H1 2025 reached EUR 609 million (+5.5% CER), per the Sanofi H1 2025 financial report (SEC Form 6-K). Visit sanofi.com for MenQuadfi prescribing information.

4. Serum Institute of India Pvt. Ltd. | (Private) | Pune, India

Serum Institute of India Pvt. Ltd. (SIIPL) is the world's largest vaccine manufacturer by volume and occupies a structurally unique position in the Meningococcal Vaccines Market as the primary supplier of affordable meningococcal conjugate vaccines to low- and middle-income countries (LMICs), particularly across the 26 African meningitis belt countries. SIIPL's meningococcal franchise is built on two landmark vaccines: MenAfriVac (a serogroup A conjugate vaccine co-developed with PATH and WHO that effectively eliminated serogroup A meningococcal epidemics from the African meningitis belt following its 2010 introduction), and MenFive (a pentavalent conjugate vaccine protecting against serogroups A, C, W, Y, and X — the only licensed vaccine covering serogroup X globally — developed through a 13-year collaboration with PATH and funded by the UK Government's Foreign, Commonwealth & Development Office). SIIPL is a private company headquartered in Pune, India. Visit seruminstitute.com for MenFive product information.

5. Merck & Co., Inc. | NYSE: MRK | Rahway, New Jersey, USA

Merck & Co., Inc. (known as MSD outside the US and Canada) has been a foundational player in the meningococcal vaccines market through its legacy product Menactra (meningococcal conjugate vaccine MenACWY-D), which was the dominant quadrivalent meningococcal conjugate vaccine in the US market from its FDA approval in 2005 until the rise of Sanofi's MenQuadfi and GSK's Menveo. The US commercial landscape for Menactra changed materially in 2023, when Sanofi discontinued Menactra from US commercial supply following the successful market transition to MenQuadfi. Merck operates across 135+ countries with approximately 67,000 employees and reported FY2024 total revenues of USD 64.2 billion (confirmed via Merck FY2024 Form 10-K, filed February 2025; FY2025 total revenues were USD 65.0 billion as reported in the Merck FY2025 10-K, February 2026). Merck's vaccine strategy has pivoted toward pneumococcal vaccines (Vaxneuvance, Capvaxive) as its primary growth platform.

6. Walvax Biotechnology Co., Ltd. | SZE: 300142 | Kunming, China

Walvax Biotechnology Co., Ltd. is the leading domestic meningococcal vaccine manufacturer in China, producing and commercialising a range of meningococcal vaccines for the Chinese national immunisation programme (NIP) and private vaccination market, including MenC conjugate vaccines, MenACYW135 polysaccharide vaccines, and group A/C conjugate vaccines. Walvax's Hualan Biological Engineering subsidiary — one of China's largest vaccine manufacturers — received NMPA (China's National Medical Products Administration) approval for a new meningococcal vaccine in July 2024, expanding the portfolio available to China's NIP market. Walvax is listed on the Shenzhen Stock Exchange (SZE: 300142) and reported approximately CNY 4.0 billion in total revenues in FY2024 (per listed annual report). Visit walvax.com for domestic China vaccine product information.

7. Bavarian Nordic A/S | OMX: BAVA | Hellerup, Denmark

Bavarian Nordic A/S is a pure-play vaccine company headquartered in Denmark that participates in the Meningococcal Vaccines Market through early-stage pipeline activities rather than currently marketed meningococcal products. Bavarian Nordic's commercial portfolio is concentrated in its Travel Health vaccines (rabies, tick-borne encephalitis, mpox/smallpox, chikungunya/Vimkunya) and Public Preparedness (mpox/smallpox) segments. The company reported total FY2025 revenue of DKK 6,244 million (confirmed via Bavarian Nordic Annual Report 2025, published March 12, 2026, audited results in line with preliminary results of February 12, 2026), comprising DKK 2,963 million from Travel Health (+30% year-on-year) and DKK 3,105 million from Public Preparedness (mpox vaccines). The company operates in approximately 50+ countries through its own commercial infrastructure and distribution partnerships. Visit bavarian-nordic.com for pipeline information.

8. Bio-Manguinhos (Fiocruz) | Government Entity | Rio de Janeiro, Brazil

Bio-Manguinhos is the vaccine manufacturing arm of the Oswaldo Cruz Foundation (Fiocruz), the Brazilian Ministry of Health's primary public health research and production institution. Bio-Manguinhos occupies a structurally distinct position in the Meningococcal Vaccines Market as the exclusive domestic supplier of meningococcal C conjugate vaccine to Brazil's National Immunisation Programme (Programa Nacional de Imunizações, PNI) — one of the world's most comprehensive government-funded vaccination programmes, covering Brazil's population of approximately 215 million. As a government entity, Bio-Manguinhos does not disclose commercial revenues; its meningococcal vaccine activity is measured by doses produced and delivered to the Brazilian PNI. Explore Fiocruz's vaccine programme at bio.fiocruz.br.

9. Incepta Pharmaceuticals Ltd. | (Private) | Dhaka, Bangladesh

Incepta Pharmaceuticals Ltd. is one of Bangladesh's largest pharmaceutical manufacturers and participates in the Meningococcal Vaccines Market as a regional manufacturer and distributor of meningococcal polysaccharide vaccines in South Asia. Incepta's meningococcal vaccine activities are concentrated in Bangladesh's domestic travel vaccination market and private clinic sector, where meningococcal vaccination demand is driven by Hajj and Umrah pilgrimage requirements (meningococcal vaccination is mandatory for entry to Saudi Arabia for all pilgrims), international travel to high-risk regions, and growing private-sector awareness of meningococcal disease among urban middle-class populations. Incepta is a private company and does not publish financial results. Visit incepta.com for product information.

10. BIO-MED Pvt. Ltd. | (Private) | Mumbai, India

BIO-MED Pvt. Ltd. is an Indian pharmaceutical and vaccine manufacturer that participates in the Meningococcal Vaccines Market through the production of meningococcal polysaccharide vaccines for the domestic Indian market. The company is licensed by India's Central Drugs Standard Control Organisation (CDSCO) for meningococcal vaccine manufacturing and serves India's travel vaccination sector, private clinic networks, and government public sector tenders. India's meningococcal vaccines market is projected to grow at approximately 9.9% CAGR from 2026 to 2033, reaching an estimated USD 135.5 million by 2033 (per Grand View Research), driven by growing awareness, expanding NIP discussions, and rising travel vaccination demand. BIO-MED is a private company and does not disclose financial results.

M&A and Regulatory Activity Tracker (2023–2026)

The Meningococcal Vaccines Market has undergone accelerating regulatory and strategic activity in 2023–2026, dominated by the dual approval of pentavalent MenABCWY vaccines by Pfizer and GSK, Sanofi's infant MenACWY label expansion, and Serum Institute's deployment of MenFive for outbreak response in Africa. Market Research Future tracks the following verified transactions and regulatory milestones:

Key Trend: MRFR analysis identifies the pentavalent vaccine consolidation wave — anchored by Penbraya (Pfizer, Oct 2023) and Penmenvy (GSK, Feb 2025) approvals and the ACIP April 2025 co-administration recommendation — as the single most commercially consequential structural shift in the meningococcal vaccines market since the introduction of conjugate technology, with peak combined sales potential of USD 2–4 billion if adolescent immunisation completion rates improve materially from the current baseline of approximately 32% receiving at least one MenACWY or MenB dose in the US.

R&D Investment & Innovation Signals

• Pfizer's Penbraya received FDA approval in October 2023 as the first pentavalent meningococcal vaccine globally, combining MenB (from Trumenba) and MenACWY (from Nimenrix) antigens in a two-dose schedule for ages 10–25, establishing the clinical and regulatory template for the pentavalent vaccine category and enabling ACIP to issue a co-administration recommendation in April 2025.

• GSK's Penmenvy received FDA approval in February 2025 for individuals aged 10–25, with the European Medicines Agency acceptance process ongoing. GSK has guided peak sales of USD 1–2 billion for Penmenvy, supported by the combination of Bexsero's established MenB market presence and Menveo's MenACWY formulary coverage across US commercial payers. Total GSK meningitis vaccine sales reached GBP 1.6 billion in FY2025 (+12%), confirmed via the GSK FY2025 Full Year Results Announcement (February 4, 2026).

• Sanofi's MenQuadfi received FDA approval for infants aged 6 weeks to 23 months in May 2025 — the broadest infant MenACWY label in the US market — restoring Sanofi's pediatric meningococcal conjugate market presence following the 2023 discontinuation of Menactra's US supply, and opening the estimated USD 400 million US infant meningococcal vaccine segment.

• Serum Institute of India's MenFive was deployed for the first time in March 2024 in Nigeria for outbreak response covering approximately 1 million individuals, representing the first real-world use of a licensed MenACWYX conjugate vaccine in an outbreak setting. The WHO SAGE recommendation in October 2023 for MenFive in all 26 meningitis belt countries has set in motion mass campaign procurement projections for 2025–2027.

• Serum Institute of India's CDSCO Phase III approval in August 2024 for a freeze-dried MenACWYX polysaccharide conjugate vaccine confirms the company's pipeline progression toward a next-generation formulation that may offer improved thermostability for deployment in resource-limited settings beyond the existing MenFive liquid formulation.